The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
GLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, suggesting detection bias was behind the increased cancer diagnosis rate ...
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.
Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP ...
Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).